Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease.
Identifieur interne : 004724 ( PubMed/Curation ); précédent : 004723; suivant : 004725Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease.
Auteurs : M. Zappia [Italie] ; R. Montesanti ; R. Colao ; D. Branca ; G. Nicoletti ; U. Aguglia ; A. QuattroneSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1997.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (diagnostic use), Drug Administration Schedule, Female, Humans, Levodopa (administration & dosage), Levodopa (diagnostic use), Long-Term Care, Male, Middle Aged, Neurologic Examination (drug effects), Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Prognosis, Psychomotor Performance (drug effects), Psychomotor Performance (physiology), Reaction Time (drug effects), Reaction Time (physiology), Receptors, Dopamine (drug effects), Receptors, Dopamine (physiology).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Levodopa.
- chemical , diagnostic use : Antiparkinson Agents, Levodopa.
- diagnosis : Parkinson Disease.
- drug effects : Neurologic Examination, Psychomotor Performance, Reaction Time, Receptors, Dopamine.
- drug therapy : Parkinson Disease.
- physiology : Psychomotor Performance, Reaction Time, Receptors, Dopamine.
- physiopathology : Parkinson Disease.
- Aged, Drug Administration Schedule, Female, Humans, Long-Term Care, Male, Middle Aged, Prognosis.
Abstract
Short-term challenges with dopaminergic agents are used in patients with idiopathic Parkinson's disease (PD) to predict the therapeutic effect of sustained levodopa treatment, but false-negative results often occur. We prospectively evaluated 74 patients with clinically diagnosed IPD and compared the predictive value of a short-term levodopa test assessed by movement time (MT) with the predictive value obtained by the evaluation with the motor examination part of the Unified Parkinson's Disease Rating Scale (UPDRS-ME). The response to long-term levodopa was accurately predicted in 96% of patients by assessing the response to the short-term test with MT and in 80% of cases with UPDRS-ME. Similar predictive values were obtained by separately analyzing 21 de novo patients. The short-term test also accurately predicted the magnitude of improvement with long-term treatment. We conclude that the predictive value for long-term dopaminergic responsiveness may be further enhanced by evaluating the short-term pharmacologic challenges with MT analysis. This is particularly useful to select de novo patients for drug trials with dopaminergic agents.
DOI: 10.1002/mds.870120118
PubMed: 8990062
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004724
Links to Exploration step
pubmed:8990062Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease.</title><author><name sortKey="Zappia, M" sort="Zappia, M" uniqKey="Zappia M" first="M" last="Zappia">M. Zappia</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Neurology, School of Medicine in Catanzaro, University of Reggio Calabria, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Neurology, School of Medicine in Catanzaro, University of Reggio Calabria</wicri:regionArea></affiliation></author><author><name sortKey="Montesanti, R" sort="Montesanti, R" uniqKey="Montesanti R" first="R" last="Montesanti">R. Montesanti</name></author><author><name sortKey="Colao, R" sort="Colao, R" uniqKey="Colao R" first="R" last="Colao">R. Colao</name></author><author><name sortKey="Branca, D" sort="Branca, D" uniqKey="Branca D" first="D" last="Branca">D. Branca</name></author><author><name sortKey="Nicoletti, G" sort="Nicoletti, G" uniqKey="Nicoletti G" first="G" last="Nicoletti">G. Nicoletti</name></author><author><name sortKey="Aguglia, U" sort="Aguglia, U" uniqKey="Aguglia U" first="U" last="Aguglia">U. Aguglia</name></author><author><name sortKey="Quattrone, A" sort="Quattrone, A" uniqKey="Quattrone A" first="A" last="Quattrone">A. Quattrone</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1997">1997</date><idno type="RBID">pubmed:8990062</idno><idno type="pmid">8990062</idno><idno type="doi">10.1002/mds.870120118</idno><idno type="wicri:Area/PubMed/Corpus">004724</idno><idno type="wicri:Area/PubMed/Curation">004724</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease.</title><author><name sortKey="Zappia, M" sort="Zappia, M" uniqKey="Zappia M" first="M" last="Zappia">M. Zappia</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Neurology, School of Medicine in Catanzaro, University of Reggio Calabria, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Neurology, School of Medicine in Catanzaro, University of Reggio Calabria</wicri:regionArea></affiliation></author><author><name sortKey="Montesanti, R" sort="Montesanti, R" uniqKey="Montesanti R" first="R" last="Montesanti">R. Montesanti</name></author><author><name sortKey="Colao, R" sort="Colao, R" uniqKey="Colao R" first="R" last="Colao">R. Colao</name></author><author><name sortKey="Branca, D" sort="Branca, D" uniqKey="Branca D" first="D" last="Branca">D. Branca</name></author><author><name sortKey="Nicoletti, G" sort="Nicoletti, G" uniqKey="Nicoletti G" first="G" last="Nicoletti">G. Nicoletti</name></author><author><name sortKey="Aguglia, U" sort="Aguglia, U" uniqKey="Aguglia U" first="U" last="Aguglia">U. Aguglia</name></author><author><name sortKey="Quattrone, A" sort="Quattrone, A" uniqKey="Quattrone A" first="A" last="Quattrone">A. Quattrone</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1997" type="published">1997</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (diagnostic use)</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Levodopa (diagnostic use)</term><term>Long-Term Care</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Prognosis</term><term>Psychomotor Performance (drug effects)</term><term>Psychomotor Performance (physiology)</term><term>Reaction Time (drug effects)</term><term>Reaction Time (physiology)</term><term>Receptors, Dopamine (drug effects)</term><term>Receptors, Dopamine (physiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term><term>Psychomotor Performance</term><term>Reaction Time</term><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Psychomotor Performance</term><term>Reaction Time</term><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Long-Term Care</term><term>Male</term><term>Middle Aged</term><term>Prognosis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Short-term challenges with dopaminergic agents are used in patients with idiopathic Parkinson's disease (PD) to predict the therapeutic effect of sustained levodopa treatment, but false-negative results often occur. We prospectively evaluated 74 patients with clinically diagnosed IPD and compared the predictive value of a short-term levodopa test assessed by movement time (MT) with the predictive value obtained by the evaluation with the motor examination part of the Unified Parkinson's Disease Rating Scale (UPDRS-ME). The response to long-term levodopa was accurately predicted in 96% of patients by assessing the response to the short-term test with MT and in 80% of cases with UPDRS-ME. Similar predictive values were obtained by separately analyzing 21 de novo patients. The short-term test also accurately predicted the magnitude of improvement with long-term treatment. We conclude that the predictive value for long-term dopaminergic responsiveness may be further enhanced by evaluating the short-term pharmacologic challenges with MT analysis. This is particularly useful to select de novo patients for drug trials with dopaminergic agents.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">8990062</PMID><DateCreated><Year>1997</Year><Month>04</Month><Day>02</Day></DateCreated><DateCompleted><Year>1997</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>1997</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>103-6</MedlinePgn></Pagination><Abstract><AbstractText>Short-term challenges with dopaminergic agents are used in patients with idiopathic Parkinson's disease (PD) to predict the therapeutic effect of sustained levodopa treatment, but false-negative results often occur. We prospectively evaluated 74 patients with clinically diagnosed IPD and compared the predictive value of a short-term levodopa test assessed by movement time (MT) with the predictive value obtained by the evaluation with the motor examination part of the Unified Parkinson's Disease Rating Scale (UPDRS-ME). The response to long-term levodopa was accurately predicted in 96% of patients by assessing the response to the short-term test with MT and in 80% of cases with UPDRS-ME. Similar predictive values were obtained by separately analyzing 21 de novo patients. The short-term test also accurately predicted the magnitude of improvement with long-term treatment. We conclude that the predictive value for long-term dopaminergic responsiveness may be further enhanced by evaluating the short-term pharmacologic challenges with MT analysis. This is particularly useful to select de novo patients for drug trials with dopaminergic agents.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zappia</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neurology, School of Medicine in Catanzaro, University of Reggio Calabria, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montesanti</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Colao</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Branca</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Nicoletti</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Aguglia</LastName><ForeName>U</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Quattrone</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008134">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011597">Psychomotor Performance</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011930">Reaction Time</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011954">Receptors, Dopamine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8990062</ArticleId><ArticleId IdType="doi">10.1002/mds.870120118</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004724 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 004724 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:8990062
|texte= Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:8990062" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |